Alector (NASDAQ:ALEC) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Alector (NASDAQ:ALEC) released its quarterly earnings data on Wednesday. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09, Zacks reports. The company had revenue of $15.08 million for the quarter, compared to analysts’ expectations of $16.04 million. Alector had a negative net margin of 125.11% and a negative return on equity of 71.80%. During the same quarter in the prior year, the firm earned $0.02 EPS.

Alector Stock Down 0.8 %

Alector stock traded down $0.04 during midday trading on Friday, hitting $5.06. 91,997 shares of the stock were exchanged, compared to its average volume of 658,808. Alector has a 52-week low of $3.66 and a 52-week high of $8.90. The business’s 50-day moving average price is $5.08 and its 200-day moving average price is $5.61. The stock has a market capitalization of $487.71 million, a price-to-earnings ratio of -3.70 and a beta of 0.72.

Insider Buying and Selling at Alector

In other news, CEO Arnon Rosenthal sold 25,135 shares of Alector stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total transaction of $120,648.00. Following the sale, the chief executive officer now directly owns 1,975,245 shares in the company, valued at approximately $9,481,176. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Marc Grasso sold 6,920 shares of Alector stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total value of $33,216.00. Following the completion of the transaction, the chief financial officer now directly owns 138,037 shares in the company, valued at $662,577.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Arnon Rosenthal sold 25,135 shares of Alector stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $4.80, for a total value of $120,648.00. Following the transaction, the chief executive officer now directly owns 1,975,245 shares of the company’s stock, valued at approximately $9,481,176. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,095 shares of company stock worth $192,456. Insiders own 9.10% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ALEC shares. Cantor Fitzgerald restated an “overweight” rating on shares of Alector in a report on Monday, July 29th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Alector in a research note on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.